Abstract: The invention relates to a method for manufacturing a tyre, wherein the tyre comprises a metal component, a textile component and a cured rubber based component bonded together by means of curing, and wherein the cured rubber based component comprises lignin that has been treated by hydrothermal carbonization. The invention further relates to use of lignin that has been treated by hydrothermal carbonization in a rubber based component of a pneumatic tyre.

Abstract: The invention relates to a pneumatic tire for a vehicle a method for manufacturing such tire, wherein the tire comprises a metal component, a textile component and a cured rubber based component bonded together by means of curing, and wherein the cured rubber based component comprises lignin that has been treated by hydrothermal carbonization. The invention further relates to use of lignin that has been treated by hydrothermal carbonization in a rubber based component of a pneumatic tire.

Abstract: The invention relates to a method for manufacturing a tyre, wherein the tyre comprises a metal component, a textile component and a cured rubber based component bonded together by means of curing, and wherein the cured rubber based component comprises lignin that has been treated by hydrothermal carbonization. The invention further relates to use of lignin that has been treated by hydrothermal carbonization in a rubber based component of a pneumatic tyre.

Abstract: The invention relates to a pneumatic tyre for a vehicle a method for manufacturing such tyre, wherein the tyre comprises a metal component, a textile component and a cured rubber based component bonded together by means of curing, and wherein the cured rubber based component comprises lignin that has been treated by hydrothermal carbonization. The invention further relates to use of lignin that has been treated by hydrothermal carbonization in a rubber based component of a pneumatic tyre.

Abstract: The present invention relates to the use of a gene transfer product to reduce hyperplastic connective tissue growth after tissue trauma or implantation of a medical device. The present invention also relates to a medical device with improved biological properties for an at least partial contact with blood, bodily fluids and/or tissues when introduced in a mammalian body, which device comprises a core and a nucleic acid, encoding a product capable of leading to production of extracellular superoxide dismutase present in a biologically compatible medium. Said nucleic acid encodes a translation or transcription product, which is capable of inhibiting hyperplastic connective tissue growth and promoting endothelialisation in vivo at least partially on a synthetic surface of said core. The present invention also relates to a method of producing a medical device according to the invention.

Abstract: The present invention relates to a medical device with improved biological properties for an at least partial contact with blood, bodily fluids and/or tissues when introduced in a mammalian body, which device comprises a core and a nucleic acid present in a biologically compatible medium. Said nucleic acid encodes a translation or transcription product, which is capable of promoting endothelialisation in vivo at least partially on a synthetic surface of said core. The present invention also relates to a method of producing a medical device according to the invention. Further, the present invention also relates to a method of improving a mammalian, preferably human, body's biocompatibility with a synthetic surface, which method comprises introducing a device according to the invention in the body with an at least partial contact with blood, bodily fluids and/or tissues and administering a nucleic acid present in a biologically compatible medium to the surroundings thereof.